Análisis de la acción Fennec Pharmaceuticals Inc (FENC)FENCFennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Fennec Pharmaceuticals Inc is a good buy right now, as it currently trades at $9.98, significantly below analyst price targets of $16 and $18. The company has shown a robust revenue growth of 72.7% year-over-year in Q1 2026, indicating strong demand for its product PEDMARK. Additionally, the forward P/E ratio is a favorable 10.57, suggesting potential for earnings growth. However, the main risk is the current RSI of 35.90, indicating the stock is nearing oversold territory, which may lead to short-term volatility.

1 analysts cover FENC: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 14.67.